ACY-738 - 99%, high purity , CAS No.1375465-91-0, Inhibitor of histone deacetylase 1;Inhibitor of histone deacetylase 2;Inhibitor of histone deacetylase 3;Inhibitor of histone deacetylase 6

In stock
Item Number
A414096
Grouped product items
SKUSizeAvailabilityPrice Qty
A414096-2mg
2mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$56.90
A414096-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$117.90
A414096-10mg
10mg
2
$212.90
A414096-50mg
50mg
2
$581.90
A414096-100mg
100mg
2
$771.90

HDAC6 Selective Inhibitors

Basic Description

Specifications & PurityMoligand™, ≥99%
Biochemical and Physiological MechanismsACY-738 inhibits HDAC6 with low nanomolar potency (IC50=1.7 nM) and a selectivity of 60- to 1500-fold over class I HDACs.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of histone deacetylase 1;Inhibitor of histone deacetylase 2;Inhibitor of histone deacetylase 3;Inhibitor of histone deacetylase 6
Product Description

Information

ACY-738 inhibitsHDAC6with low nanomolar potency (IC50=1.7 nM) and a selectivity of 60- to 1500-fold over class I HDACs.


Targets

HDAC6 (Cell-free) 1.7 nM


In vivo

ACY-738 induces dramatic increases in α-tubulin acetylation in brain and stimulate mouse exploratory behaviors in novel, but not familiar environments. ACY-738 has the antidepressant-like properties. Elimination of ACY-738 from plasma is rapid, with plasmatic half-life of 12\u2009min and concentration below 10\u2009ng/ml after 2\u2009h. ACY-738 rapidly distributes to the brain leading to a total drug exposure in CNS comparable to that of peripheral tissues. ACY-738 decreases several characteristics of SLE (Systemic lupus erythematosus) in NZB/W mice by dictating B cell development in the bone marrow. ACY-738 treatment increases the percentage of B cells in early developmental stages, while decreasing the percentage of cells in late pre-B cell fraction F. ACY-738 regulation of BM B cell development could be due to regulation developmental checkpoints known to be dysfunctional during SLE.


Cell Research(from reference)

Cell lines:Undifferentiated RN46A-B14 cells 

Concentrations:2.5\u2009μM 

Incubation Time:4 h 

Product Properties

ALogP1.325
HBD Count2
Rotatable Bond4

Associated Targets(Human)

HDAC6 Tclin Histone deacetylase 6 (5 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HDAC1 Tclin Histone deacetylase 1 (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HDAC2 Tclin Histone deacetylase 2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HDAC3 Tclin Histone deacetylase 3 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
HDAC2 Tclin Histone deacetylase 2 (3971 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HDAC3 Tclin Histone deacetylase 3 (3654 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HepG2 (196354 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
697 (196 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Hdac1 Histone deacetylase 1 (93 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Schistosoma mansoni (6170 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid504771587
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/504771587
IUPAC Name N-hydroxy-2-[(1-phenylcyclopropyl)amino]pyrimidine-5-carboxamide
INCHI InChI=1S/C14H14N4O2/c19-12(18-20)10-8-15-13(16-9-10)17-14(6-7-14)11-4-2-1-3-5-11/h1-5,8-9,20H,6-7H2,(H,18,19)(H,15,16,17)
InChi Key LIIWIMDSZVNYHY-UHFFFAOYSA-N
Canonical SMILES C1CC1(C2=CC=CC=C2)NC3=NC=C(C=N3)C(=O)NO
Isomeric SMILES C1CC1(C2=CC=CC=C2)NC3=NC=C(C=N3)C(=O)NO
PubChem CID 57381425
Molecular Weight 270.29

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
I2206157Certificate of AnalysisJun 04, 2024 A414096
I2206158Certificate of AnalysisJun 04, 2024 A414096
I2206156Certificate of AnalysisJun 04, 2024 A414096

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: 54 mg/mL (199.78 mM); Ethanol: 1 mg/mL (3.69 mM); Water: Insoluble;
DMSO(mg / mL) Max Solubility54
DMSO(mM) Max Solubility199.7854157
Water(mg / mL) Max Solubility<1
Molecular Weight270.290 g/mol
XLogP31.100
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Exact Mass270.112 Da
Monoisotopic Mass270.112 Da
Topological Polar Surface Area87.100 Ų
Heavy Atom Count20
Formal Charge0
Complexity345.000
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1

Specifications

References

1. LoPresti P.  (2019)  The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis..  Front Neurol,  10  (13): (519).  [PMID:31316445] [10.1021/op500134e]
2. Jochems J, Boulden J, Lee BG, Blendy JA, Jarpe M, Mazitschek R, Van Duzer JH, Jones S, Berton O.  (2014)  Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability..  Neuropsychopharmacology,  39  (2): (389-400).  [PMID:23954848] [10.1021/op500134e]

Solution Calculators

Reviews

Customer Reviews